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Toll-like receptors (TLRs) are a family of pattern recognition receptors that shape the innate
immune system by identifying pathogen-associated molecular patterns and host-derived
damage-associated molecular patterns. TLRs are widely expressed on both immune
cells and non-immune cells, including hematopoietic stem and progenitor cells, effector
immune cell populations, and endothelial cells. In addition to their well-known role in the
innate immune response to acute infection or injury, accumulating evidence supports
a role for TLRs in the development of hematopoietic and other malignancies. Several
hematopoietic disorders, including lymphoproliferative disorders and myelodysplastic
syndromes, which possess a high risk of transformation to leukemia, have been linked to
aberrant TLR signaling. Furthermore, activation of TLRs leads to the induction of a number of proinflammatory cytokines and chemokines, which can promote tumorigenesis
by driving cell proliferation and migration and providing a favorable microenvironment for
tumor cells. Beyond hematopoietic malignancies, the upregulation of a number of TLRs
has been linked to promoting tumor cell survival, proliferation, and metastasis in a variety
of cancers, including those of the colon, breast, and lung. This review focuses on the
contribution of TLRs to hematopoietic malignancies, highlighting the known direct and
indirect effects of TLR signaling on tumor cells and their microenvironment. In addition,
the utility of TLR agonists and antagonists as potential therapeutics in the treatment of
hematopoietic malignancies is discussed.
Keywords: toll-like receptors, MyD88, HSC, myelodysplastic syndrome, leukemia

INTRODUCTION
Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that play a central
role in innate immunity. TLRs are expressed on a wide variety of effector immune and stromal cell
types, as well as hematopoietic stem and progenitor cells (HSPCs) (1–3), and signaling through
these receptors is essential to mounting an effective immune response to an acute infection or injury.
However, while TLR signaling is important to the normal immune response, enhanced or aberrant
TLR signaling is associated with ineffective hematopoiesis and hematopoietic malignancy (4, 5).
Most notably, enhanced expression of components of the TLR signaling pathway, as well as activating mutations in some cases, are associated with lymphoproliferative disorders and myelodysplastic
syndromes (MDS) (6–16).
This review focuses on the contribution of TLR signaling to impaired hematopoiesis and hematopoietic malignancy. We will explore the role of cell-autonomous aberrant TLR signaling to loss
of normal HSPC function and leukemogenesis, as well as the non-cell-autonomous effects of TLR
signaling that may contribute to disease pathogenesis. Finally, we will discuss the utility of TLRs and
their downstream effectors as therapeutic targets in hematopoietic neoplasms.
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TLR SIGNALING OVERVIEW

mobilization, and differentiation of HSCs and committed
progenitors (2, 4, 5, 33–37). In fact, recent studies have shown
that proinflammatory signals, including TLR4–MyD88–NF-κB
stimulation, are necessary for HSPC emergence in zebra fish
and mouse embryos (38, 39). Thus, TLR signaling contributes
to early hematopoiesis and continues to influence HSPCs
into adulthood. Notably, sustained exposure to TLR signals is
associated with loss of normal HSC function. Chronic in vivo
treatment of mice with the TLR4 agonist LPS, for example,
leads to HSC cycling and a promotion of myeloid differentiation with a loss of HSC repopulating activity in transplantation
experiments (4). Similarly, systemic exposure of mice to the
TLR2 agonist PAM3CSK4 leads to an expansion of bone marrow
and spleen phenotypic HSCs, but a loss of bone marrow HSC
self-renewal (40). Conversely, loss of TLR signaling (in Tlr2−/−,
Tlr4−/−, Tlr9−/−, or MyD88−/− deficient mice) is associated with
enhanced HSC repopulating activity (41, 42). This last point
illustrates that even in the absence of overt infection or other
insult, TLR signaling regulates baseline hematopoiesis.
The effects of TLR signaling on HSPCs are likely mediated
by both cell-autonomous and cell non-autonomous mechanisms.
Evidence for a direct, cell-autonomous role for TLR signaling
in regulating HSCs comes from in vitro studies showing that
incubation of HSPCs with TLR agonists induces cell cycling
and myeloid differentiation (1, 2). Furthermore, Megias and
colleagues demonstrated that purified HSPCs (c-Kit+ Sca-1+
Lineage− IL7Ra− cells) from wild-type mice transplanted into
Tlr2−/−, Tlr4−/−, or MyD88−/− recipients differentiated into macrophages in response to specific TLR ligands (37). This approach,
by removing a potential contribution of soluble mediators of
the effects of TLR signals from other hematopoietic or stromal
cells, supports the idea that TLR ligands can have direct, cellautonomous effects on HSPCs in vivo. In agreement with this
idea, we recently reported that systemic exposure of mice to a
TLR2 ligand regulates HSCs, in part, via cell-autonomous TLR2
signaling (40). Chimeric mice were generated in which a mixture
of Tlr2−/− and WT bone marrow was transplanted into lethally
irradiated Tlr2−/− recipients. Treatment of these chimeras with
the TLR2 agonist PAM3CSK4 led to a relatively greater expansion
of WT HSCs compared to Tlr2−/− HSCs, supporting a role for
cell-autonomous TLR2 signaling in regulating HSCs.
While in vitro and chimeric animal studies endorse a role
for cell-autonomous TLR signaling in the regulation of immature hematopoietic cells, a large number of proinflammatory
cytokines are produced by effector immune cells and progenitors
in response to TLR ligands, and these cytokines are known to
influence HSPC cycling, differentiation, survival, and function,
as well (43). For example, several recent studies have shown that
systemic TLR4 stimulation in mice promotes HSC mobilization
indirectly via production of granulocyte-colony stimulating
factor (G-CSF) by endothelial cells (36, 44). Systemic TLR2
stimulation in mice also leads to G-CSF production, as well as
increased serum levels of TNFα, and inhibition of these cytokines
partially rescues the proliferation and mobilization of HSPCs in
response to TLR2 agonist treatment (40). Finally, using a microfluidic single-cell proteomics platform, Zhao et al. showed that
TLR2 and TLR4 ligands stimulate abundant cytokine production

A total of 12 TLR family members have been described in
mice, and 10 in humans (17). In addition to identifying foreign
pathogen-associated molecular patterns [PAMPS, e.g., pepti
doglycans, lipopolysaccharide (LPS)], TLRs recognize a wide
variety of non-pathogen-associated ligands. These so-called
damage-associated molecular patterns (DAMPS) include various
endogenous by-products of cellular damage, such as free nucleic
acids and extracellular matrix components (18). TLRs are widely
expressed on both immune cells and non-immune cells, including
dendritic cells, macrophages, lymphocytes, HSPCs, and endothelial cells (3, 19–22). Some of the TLRs are localized to the plasma
membrane (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11), while
others are found in endosomes (TLR3, TLR7, TLR8, and TLR9).
In general, the TLRs act as homodimers, with the exception of
TLR2, which heterodimerizes with TLR1 or TLR6 (23–25). Each
TLR has a unique profile of known ligands, dictated in part by
their subcellular localization.
Signaling through TLRs requires the recruitment of intracellular adaptor proteins, with all TLRs, except TLR3, using the
myeloid differentiation primary response gene 88 (MyD88).
Following recruitment of MyD88 to activated TLRs, this adaptor
complexes with the serine–threonine kinase interleukin-1 receptor-associated kinase 4 (IRAK4) (26), which in turn recruits other
IRAK family members (IRAK1 and IRAK2), forming a complex
referred to as the “Myddosome” (27). IRAK1 interacts with the
tumor necrosis factor (TNF) R-associated factor 6 (TRAF6) E3
ubiquitin ligase. TRAF6 then participates in the activation of
transforming growth factor beta-activated kinase 1 (TAK1),
which in turn activates the nuclear factor k-light-
chainenhancer of activated B cells (NF-κB) and mitogen-activated
protein kinase (MAPK) pathways and promotes the expression
of various proinflammatory cytokines (e.g., interleukin-1 (IL-1),
IL-6, IL-8, and TNFα) (28).
Toll-like receptor3 functions independently of MyD88, utilizing instead the adaptor protein TIR-domain-containing adaptorinducing interferon-B (TRIF) (29). TRIF, upon binding to TRAF3,
recruits the IKK-related kinases TBK1 and IKKε and ultimately
activates interferon regulatory factor-3 (IRF3) and stimulates the
production of type I interferons (IFNs) (30). In addition, TRIF
interacts with TRAF6 and contributes to MyD88-independent
activation of NF-κB and MAPKs (31). TLR4 uniquely utilizes
both MyD88- and TRIF-dependent pathways (Figure 1) (32).

TLR SIGNALING AND HEMATOPOIETIC
STEM AND PROGENITOR CELLS
In response to acute infection or injury, TLR signaling promotes
the production of proinflammatory cytokines and assists with
the development of the adaptive immune response. Recent
studies suggest that outside of their well-known role in
responding to pathogens and other insults by stimulating
effector immune cells, TLRs can influence hematopoiesis from
the level of the hematopoietic stem cell (HSC). Both mouse
and human HSCs express TLRs (1–3), and accumulating data
demonstrate that TLR ligands can influence the proliferation,
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FIGURE 1 | TLR signaling overview. TLR signaling may be divided into the MyD88-dependent and MyD88-independent (TRIF-dependent) signaling pathways.
In the MyD88-dependent pathway, activation of MyD88 from membrane-bound TLR ligation forms complexes with IRAKs1, 2, and 4, leading to an interaction with
TRAF6. Ultimately, the NF-κB and MAPK pathways are activated, resulting in the production of inflammatory cytokines. The TRIF-dependent (MyD88-independent)
pathway requires TRIF binding to TRAF3, which recruits TBK1 and IKKε, thereby activating IRF3. Endosomal TLRs (3, 7, 8, and 9) act through the IRAK–TRAF6
complex to activate IRF7. Together, IRF3 and IRF7 stimulate type I interferon production.

TLR SIGNALING AND HEMATOPOIETIC
MALIGNANCY

by short-term HSCs and multipotent progenitors, which in turn
promote myeloid differentiation in an autocrine or paracrine
manner (45). Thus, TLR ligands influence HSPC cycling, differentiation, and mobilization both directly, via cell-autonomous
signaling, and indirectly, via non-cell-autonomous production of
proinflammatory cytokines.
Frontiers in Immunology | www.frontiersin.org

As noted above, sustained or dysregulated TLR signaling, via
direct cell-autonomous as well as indirect mechanisms involving
inflammatory cytokines, may contribute to loss of normal HSC
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function. Furthermore, numerous recent studies have demonstrated enhanced TLR expression and signaling in hematopoietic
malignancies (Table 1). For example, activated TLR signaling
and overexpression of TLRs and their downstream effectors are
associated with MDS (11–15), a heterogeneous group of HSC
disorders associated with ineffective hematopoiesis, myeloid
dysplasia, and a high risk of transformation to acute leukemia. In
addition, an activating mutation in MyD88 is commonly found
in lymphoid malignancies (6–10, 46). While the exact role for
this enhanced TLR signaling in these malignancies is not clear,
it likely has, as with normal HSPCs, both cell-autonomous and
non-autonomous effects on premalignant and malignant cells.
Below, we discuss, in further detail, our current understanding
of the role of TLR signaling in these and other hematopoietic

malignancies and discuss the potential utility of TLR signaling as
a therapeutic target in their treatment.

ABERRANT TLR SIGNALING IN MDS
Myelodysplastic syndromes are a heterogeneous group of clonal
HSC disorders characterized by peripheral cytopenias, myeloid
dysplasia, and a high risk of transformation to acute leukemia
(47). MDS is one of the most common hematopoietic malignancies of older adulthood, and it occurs less frequently in children
and young adults. The disease may occur de novo, or may arise
following prior cytotoxic therapies. Distinct subtypes of MDS are
identified based on genetic and morphological features, and in
children MDS is often associated with inherited bone marrow
failure syndromes (48). Regardless of the underlying genetic
landscape, deregulation of innate immune signaling, and, in
particular, enhanced TLR signaling, is associated with MDS
(49, 50). Thus, TLRs and their downstream effectors are attractive therapeutic targets in MDS, as stem cell transplantation is
presently the only curative therapy and is only feasible for a subset
of patients (51).
Increased expression of multiple TLRs and signaling intermediates has been reported in MDS, as well as a loss of TLR signaling
repressors. In patients with the deletion 5q (del (5q)) subtype of
MDS, for example, loss of two micro-RNAs, miR-145 and miR146a, which normally inhibit the TLR signaling intermediates
TIR-domain-containing adaptor protein (TIRAP that associates
with MyD88 and assists in the formation of the Myddosome)
and TRAF6, leads to inappropriate activation of TLR signaling
(14). This, in turn, results in excessive IL-6 production, which
contributes to ineffective hematopoiesis, including thrombocytosis, megakaryocyte dysplasia, and neutropenia. Additionally,
enforced expression of TRAF6 or knockdown of miR-145 or
miR-146 in murine HSCs phenocopies some of the features of
del (5q) MDS, suggesting that inappropriately activated TLR
pathway signaling within the HSCs contributes to disease pathogenesis (14). Recently, Varney et al. (13) described an additional
mechanism for increased TRAF6 expression in del (5q) MDS
involving haploinsufficiency for TRAF-interacting protein with
forkhead-associated domain B (TIFAB). TIFAB forms a complex
with TRAF6, reducing its stability by a lysosome-dependent
mechanism, and mice transplanted with Tifab−/− HSPCs display
a bone marrow failure like disease with cytopenias and myeloid
differentiation skewing. Furthermore, re-expression of TIFAB in
human MDS/AML cell lines with low endogenous TIFAB significantly reduced leukemic colony formation and cell survival. Thus,
along with miR-146a, TIFAB helps to limit TRAF6 expression
and regulate HSPC differentiation and function.
In addition to the data supporting a role for enhanced TLR
signaling in del (5q) MDS, numerous studies have shown
increased expression of TLRs and TLR pathway intermediates
in patients with all types of MDS. For example, Maratheftis and
colleagues showed increased TLR4 expression in the CD34+ cells
of patients with MDS in a small series of 21 cases, and this expression was associated with increased apoptosis (11). Velegraki
and colleagues (52) found increased expression of TLR4 and
upregulation of TLR4-mediated signaling in the CD14+ bone

TABLE 1 | Overview of toll-like receptors associated with hematologic
malignancies.
Toll-like
receptor

Hematologic malignancy

Reference

TLR1

Myelodysplastic syndrome (MDS), acute
lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), multiple myeloma (MM),
chronic lymphocytic leukemia (CLL)

MDS: (15, 53);
ALL: (54); AML:
(63, 64); MM: (72,
73); CLL: (75)

TLR2

Myelodysplastic syndrome (MDS), acute
lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), multiple myeloma (MM),
chronic lymphocytic leukemia (CLL)

MDS: (15, 53, 57,
59, 60); ALL: (54);
AML: (62, 64); MM:
(71, 73); CLL: (75)

TLR3

Acute myeloid leukemia (AML), multiple
myeloma (MM), indolent non-Hodgkin’s
lymphoma (iNHL)

AML: (64, 88); MM:
(72, 73, 87); iNHL:
(104)

TLR4

Myelodysplastic syndrome (MDS), acute
myeloid leukemia (AML), multiple myeloma
(MM), Mantle cell lymphoma (MCL), Follicular
non-Hodgkin’s lymphoma (NHL)

(11, 52, 57, 59–61);
AML: (62, 64); MM:
(71–73); MCL: (74);
NHL: (103)

TLR5

Acute myeloid leukemia (AML), multiple
myeloma (MM)

AML: (64); MM: (73)

TLR6

Myelodysplastic syndrome (MDS), acute
lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), multiple myeloma (MM),
chronic lymphocytic leukemia (CLL)

MDS: (15, 53); ALL:
(54); AML: (64);
MM: (73); CLL: (75)

TLR7

Acute myeloid leukemia (AML), activated B-cell
(ABC) diffuse large B-cell lymphoma (DLBCL),
multiple myeloma (MM), chronic lymphocytic
leukemia (CLL)

AML: (64, 86); ABC
DLBCL: (70); MM:
(72, 73); CLL: (75)

TLR8

Acute myeloid leukemia (AML), multiple
myeloma (MM)

AML: (64, 86); MM:
(72, 73)

TLR9

Acute myeloid leukemia (AML), activated B-cell
(ABC) diffuse large B-cell lymphoma (DLBCL),
multiple myeloma (MM), chronic lymphocytic
leukemia (CLL), B-cell lymphoma (BCL)

AML: (64); ABC
DLBCL: (70); MM:
(71–73); CLL: (75);
BCL: (102)

TLR10

Acute myeloid leukemia (AML), multiple
myeloma (MM), chronic lymphocytic leukemia
(CLL)

AML: (64); MM:
(73); CLL: (75)

TLR11

Acute myeloid leukemia (AML), multiple
myeloma (MM)

AML: (64); MM: (73)

TLR12

Acute myeloid leukemia (AML), multiple
myeloma (MM)

AML: (64); MM: (73)

TLR13

Acute myeloid leukemia (AML), multiple
myeloma (MM)

AML: (64); MM: (73)
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in an MDS xenograft model (56), suggesting that IRAK1 may be
a potential therapeutic target in MDS.
Thus, multiple studies have linked increased TLR signaling
to MDS; however, the specific contribution of this signaling to
disease progression is not clear. The existing data suggest that
aberrant TLR signaling promotes ineffective hematopoiesis and
likely contributes to the cytopenias characteristic of the disease.
However, it is not at all clear whether this aberrant signaling
promotes the transformation of MDS to acute leukemia. Further
studies will be necessary to determine if TLR expression and
signaling in premalignant MDS HSCs changes upon transformation, and whether TLR stimulation contributes to the acquisition
of clonal dominance in this disease. In addition, it is not clear
to what extent enhanced TLR signaling outside of the CD34+
population contributes to MDS pathogenesis. Accumulating
evidence supports a role for the bone marrow microenvironment
in the evolution of MDS, with numerous alterations in the bone
marrow stromal and hematopoietic populations and deregulation
of inflammatory cytokine secretion contributing to ineffective
hematopoiesis. For example, myeloid-derived suppressor cells
(MDSCs), an immature myeloid population with potent T-cell
suppressive capabilities, are expanded in the bone marrow of
MDS patients (57, 58). MDSCs were first characterized in tumorbearing mice and patients with cancer and contribute to immune
escape of malignant cells. Notably, S100A9, which is a DAMP
that is increased in the plasma of MDS patients and binds TLR2
and TLR4, has been shown to stimulate the expansion and activation of MDSCs (57, 59, 60). S100A9 transgenic mice display an
accumulation and activation of MDSCs and develop progressive
multilineage cytopenias and dysplastic features characteristic of
human MDS (57). Schneider and colleagues (61) also demonstrated a link between haploinsufficiency of the ribosomal gene,
Rps14, which has been linked to the severe macrocytic anemia
observed in del (5q) MDS patients, to activation of the calcium
binding proteins, S100A8 and S100A9. The authors found that
S100A8, acting upstream of TLR4 and TNFα, contributed to a
p53-dependent erythroid-differentiation defect. Further studies
are needed to comprehensively define the different bone marrow
populations in which aberrant TLR signaling occurs in MDS and
to determine the relative contribution of cell-autonomous versus
cell non-autonomous signaling to the disease pathogenesis.

marrow cells of patient with MDS. Furthermore, they reported
that impaired clearance of apoptotic cells by macrophages in the
bone marrow of patients with MDS is associated with increased
circulating levels of the endogenous TLR agonist high mobility
group protein B1 (HMGB1), and they concluded that this contributes to enhanced proinflammatory cytokine production by
monocytes and impaired clonogenic potential of CD34+ cells in
MDS patients. More recently, Wei and colleagues demonstrated
increased expression of TLR2 and its functional binding partners,
TLR1 and TLR6, in the CD34+ cells of a series of 149 patients
with MDS (15). Furthermore, they identified an acquired, activating variant of TLR2 (TLR2-F217S) in 11% of their cohort of
individuals with MDS, which is associated with enhanced NF-κB
activation in response to TLR2 ligand exposure. This group
showed that inhibition of TLR2 in primary cultured bone marrow
CD34+ cells from patients with MDS by short hairpin RNA led to
improved erythroid colony formation in vitro, further supporting
a role for this receptor in the pathogenesis of MDS. They proposed
a model whereby augmented TLR2 signaling leads to activation
of the histone demethylase JMJD3, thus stimulating the abnormal
epigenetic activation of multiple innate immunity genes, including IL-8, and promoting ineffective hematopoiesis. Based on these
data, a phase I/II study of an anti-TLR2 antibody (OPN-305) is
underway for second-line treatment of lower-risk MDS patients
(Opsona Therapeutics, Dublin, Republic of Ireland).
Interestingly, while expression of TLR2 itself in the above
study correlated with low-risk disease by the International
Prognostic Scoring System and longer survival, higher expression of its binding partner, TLR6, was associated conversely with
higher-risk disease and increased bone marrow blasts (15). This
finding raises the intriguing possibility that the effects of TLR2
signaling in MDS may be influenced by which heterodimer pair
is stimulated (TLR1/2 versus TLR2/6). Historically, this association with different partners has been thought to expand the ligand
spectrum without altering downstream signaling (53). However,
more recent data suggest that there are heterodimer-specific differences with respect to activation of downstream pathways. For
example, Rolf and colleagues (54) demonstrated that stimulation
of acute lymphoblastic leukemia (ALL) cell lines and primary
ALL samples with the specific TLR1/2 agonist, PAM3CSK4,
versus the TLR2/6 agonist, PAM2CSK4, led to distinct activation
kinetics of the NF-κB and PI3K pathways. Furthermore, only
PAM3CSK4 sensitized ALL cells to vincristine-mediated toxicity. Further studies are needed to determine whether there are
heterodimer-specific effects of TLR2 stimulation on MDS cells,
as this could have implications for the development of targeted
therapies.
In addition to the TLRs themselves, the expression of numerous downstream signaling mediators is increased in patients
with MDS, as well. For example, increased expression of the TLR
signaling adaptor, MyD88, was found in 40% of individuals in a
cohort of 64 patients with MDS, and high expression correlated
with shorter survival (16). Similarly, IRAK1 is overexpressed in
the CD34+ cells of approximately 10–30% of patients with MDS,
with high expression associated with reduced overall survival (12,
55, 56). Pharmacologic or genetic inhibition of IRAK1 induced
cell cycle arrest and apoptosis in MDS cells and improved survival
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TLR SIGNALING IN OTHER MYELOID
MALIGNANCIES
In addition to MDS, aberrant TLR expression has been associated with other myeloid neoplasms. For example, in a study
of 103 newly diagnosed patients with acute myeloid leukemia
(AML), Rybka and colleagues found that the mRNA expression
of TLR2 and TLR4 was significantly higher in the bone marrow of
patients with myelomonocytic and monoblastic acute leukemia
compared to those with other types of AML. Furthermore, the
expression of these receptors was also higher in patients with no
response to induction therapy compared to those who achieved
complete remission, and the overall survival of patients with
higher TLR2 and TLR4 expression was significantly shorter than
that of patients with lower expression (62). One of the binding
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partners of TLR2, TLR1, was also shown to be significantly
upregulated in leukemic stem cells (LSCs) derived from 18 AML
patients as compared to normal bone marrow cells derived from
healthy donors, a finding consistent with elevated TLR1 mRNA
levels observed in MDS patients described earlier (15, 63).
The authors stimulated LSCs both in vitro and ex vivo with the
TLR2/1 agonist, PAM3CSK4, and found that agonist treatment
led to expansion, increased leukemic cell survival, and a shift
toward differentiation. Similarly, in a study of mRNA expression
of TLRs in myeloid leukemia cell lines, Okamoto and colleagues
found that 10 TLRs were expressed in the majority of leukemic
cell lines assessed (64). The authors evaluated the functionality
of the TLRs by examining cell proliferation and differentiation
upon ligand exposure. Ligand stimulation, however, failed to
trigger differentiation (contrary to what was observed in normal
bone marrow progenitors), thereby warranting further study of
the mechanism through which TLR signaling induces differentiation in normal and malignant cells.

been suggested in activated B-cell (ABC) diffuse large B-cell
lymphoma (DLBCL), where both the depletion of a number of
proteins necessary for TLR7 and TLR9 trafficking and signaling,
including UNC93B1, CD14, and PRAT4A, and pharmacologic
inhibitors of these TLRs led to cell death in vitro (70).
In addition to the activating MyD88 (L265P) mutation, the
expression of TLR signaling pathway components is increased
in lymphoid malignancies. For example, TLRs have been found
to be more highly expressed in the plasma cells obtained from
multiple myeloma patients as compared to healthy control donors
(71). Additionally, culture of human myeloma cell lines and
primary cells with TLR ligands stimulates cell growth and spares
these cells from serum deprivation or dexamethasone-induced
apoptosis via autocrine secretion of interleukin-6 (IL-6) (71–73).
In a study of Mantle cell lymphoma (MCL), an incurable B-cell
malignancy, Wang and colleagues found that the levels of TLR4
expression were significantly higher on primary MCL cells than
normal peripheral blood mononuclear cells (PBMCs) or B cells,
and activation of TLR4 by LPS promotes tumor growth and
enables MCL cells to evade the immune system via secretion
of IL-6, IL-10, and vascular endothelial growth factor (VEGF)
(74). A study of TLR expression patterns in purified leukemic
B-lymphocytes isolated from chronic lymphocytic leukemia
(CLL) patients and the MEC1 CLL cell line revealed an increased
expression of TLRs 1, 2, 6, 7, 9, and 10 (75). Further in vitro
studies demonstrated that the TLR2/1 and TLR2/6 ligands,
PAM3CSK4 and MALP-2 (mycoplasmal macrophage-activating
lipopeptide-2), protected CLL cells from spontaneous apoptosis.
Finally, single nucleotide polymorphisms (SNPs) in several TLRs
have been associated with lymphoma risk (76–79).

TLR SIGNALING IN LYMPHOID
MALIGNANCIES
In addition to myeloid malignancies, enhanced TLR signaling
has been implicated in a number of lymphoid neoplasms as
well. Notably, lymphoid malignancies are commonly associated
with a specific gain-of-function mutation in MyD88. This single
nucleotide variant leads to the substitution within the MyD88
TIR domain of a leucine residue at position 265 to a proline
(L265P), which ultimately promotes enhanced IRAK1 phosphorylation and activation of NF-κB and JAK–STAT3 signaling
with production of proinflammatory cytokines and promotion
of cell survival (6, 65). MyD88 (L265P) is highly recurrent, with
29% of a cohort of 382 patients with activated B-cell-like diffuse
large B-cell lymphoma possessing this mutation (6). The same
mutation was found in 9% of gastric mucosa-associated lymphoid
tissue (MALT) lymphomas. It was also identified in 2.9% of
patients with chronic lymphocytic leukemia and was associated
with younger age and more advanced clinical stage (7). Finally,
the L265P MyD88 mutation was found in nearly 50% of patients
with immunoglobulin M (IgM) monoclonal gammopathy of
unknown significance (MGUS) and >90% (66) of patients with
Waldenstrom macroglobulinemia (WM) (9, 10). In addition to
activating IRAK activity, Yang and colleagues (67) found that
the MyD88 (L265P) variant supports lymphoplasmacytic cell
survival in WM through stimulation of Bruton tyrosine kinase
(BTK), and suppression of BTK and IRAK1/2 had synergistic
effects on inhibiting NF-κB signaling and promoting apoptosis
in WM cells. In a study utilizing a retroviral gene transfer system
in mice, Wang and colleagues (68) demonstrated that the MyD88
(L265P) variant alone was capable of driving B cell division
in vitro in the absence of exogenous TLR ligands. However, this
proliferation was dependent upon intact signaling by the RNA/
DNA-sensing TLRs, as it was inhibited by the Unc93b13d mutation
(which disrupts exogenous antigen presentation and signaling
via TLRs 3, 7, and 9) (66, 69), TLR9 deficiency, and chloroquine
exposure (necessary for proteolytic activation of TLR ectodomains). The dependence of oncogenic MyD88 on TLRs has also
Frontiers in Immunology | www.frontiersin.org

TLR SIGNALING IN NON-HEMATOPOIETIC
MALIGNANCIES
While a detailed discussion of the role of TLR signaling in
non-hematopoietic malignancies is outside the scope of this
review, cell-intrinsic signaling for a number of TLRs has been
associated with promoting oncogenesis (80). For example, TLR2
has recently been shown to have a cell-intrinsic role in regulating
epithelial cell growth and oncogenesis. Scheeren and colleagues
(81) reported that loss of TLR2 signaling in intestinal epithelium
reduces damage-induced colitis regeneration and spontaneous
tumor formation in Apcmin/+ mice [carrying a point mutation
in the adenomatous polyposis coli (Apc) gene, which leads to
development of intestinal tract tumors]. Furthermore, TLR2 is
expressed on breast epithelia, and TLR2 agonist treatment of
luminal and basal breast epithelial cells promotes in vitro colony
growth. Conversely, TLR2 loss inhibited the growth of breast cancer cells both in vitro and in vivo. Another recent study showed
that STAT3-mediated upregulation of TLR2 expression on gastric
epithelial cells promoted cell proliferation and survival, and inhibition of TLR2 suppressed gastric tumor formation (82). CherfilsVicini et al. (83) demonstrated expression of TLR7 and TLR8 in
human primary lung cancer sections and lung tumor cell lines and
showed that stimulation of these cell lines in culture with TLR7
and TLR8 agonists led to activation of NF-κB, as well as increased
expression of the anti-apoptotic protein Bcl-2, enhanced survival,
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and chemoresistance. Additionally, He and colleagues described
the expression of functional TLR4 in human lung cancer cells (84)
and found that TLR4 stimulation led to the secretion of numerous
immunosuppressive cytokines, including VEGF and TGF-β, and
the proangiogenic chemokine IL-8, thereby inducing resistance
to TNFα and TRAIL-induced apoptosis in vitro. Finally, high
TLR9 expression was also observed in both primary lung cancer
specimens and tumor cell lines (85), and activation of the TLR9
pathway resulted in the production of monocyte chemoattractant
protein-1 (MCP-1) and the reduction of TNFα-induced apoptosis. Together, these data from non-hematopoietic malignancies
support a role for cell-autonomous TLR signaling in promoting
the growth and survival of malignant cells.

triggered caspase-8-mediated apoptosis and sensitized ALL cells
to vincristine-mediated toxicity in vitro (54). These studies support the idea that cell-autonomous TLR signaling may, in fact,
have an antitumor effect in some hematopoietic malignancies.
In addition to a potential direct antitumor effect, TLR agonists
are being used in multiple tumor types, including hematopoietic
malignancies, for their ability to elicit anticancer immune
responses (90–95). In this respect, TLR agonists act to disrupt
tolerance to tumor cells, thus facilitating the destruction of these
cells by the patient’s own immune system. As early as the 1960s,
Mathe and colleagues described enhanced survival in pediatric
leukemia patients treated with injections of the TLR agonist,
Bacille Calmette–Guérin (BCG) bacilli, which is still currently
utilized for the treatment of bladder cancer (96–98). The majority
of clinical trials utilizing TLR agonists have focused on TLR3,
TLR7/8, and TLR9, and recent studies have indicated that the
combinatorial use of TLR agonists may be beneficial for patients
whose tumors express multiple TLRs (99–101). With respect to
hematologic malignancies, three phase I/II clinical trials are currently recruiting patients to study the potential use of TLR3, TLR4,
and TLR9 agonists in combination with immunotherapeutics and
radiation therapy for the treatment of recurrent low-grade B-cell
lymphomas, T-cell lymphoma, and follicular non-Hodgkin’s lymphoma (Clinical Trial Identifiers: NCT02254772, NCT02501473,
and NCT01976585) (102–104).

TLRs AS THERAPEUTIC TARGETS
IN HEMATOPOIETIC MALIGNANCY
Treatment of hematopoietic malignancies is still largely based
on chemotherapeutic drug regimens and stem cell transplantation, and new therapies are needed. The association of enhanced
TLR expression and signaling with hematopoietic malignancies
suggests that inhibition of these receptors or their downstream
effectors may confer therapeutic benefit. As discussed above, for
example, a phase I/II study of an anti-TLR2 antibody (OPN-305,
Opsona Therapeutics, Dublin, Ireland) is currently underway for
the second-line treatment of lower-risk MDS patients based on
preclinical studies showing improved erythroid colony formation
upon TLR2 inhibition in MDS CD34+ cells in vitro. Similarly, as
the activating MyD88 L265P mutation is prevalent in multiple
lymphoid malignancies, particularly WM, inhibiting this factor
represents an attractive therapeutic strategy. Indeed, preclinical
studies have shown that loss of MyD88 or its downstream targets
(BTK, IRAK1, IRAK4) suppresses NF-κB signaling and induces
WM cell death. Ibrutinib is a BTK inhibitor that was recently
approved for the treatment of WM following a prospective,
multicenter trial that showed its efficacy with high response rates
and improved progression-free survival in previously treated
patients (46, 86).
Although the role of TLR signaling in hematopoietic malignancies is largely thought to be that of promoting disease, as
reviewed above, and inhibitors of TLR signaling, such as OPN-305
and Ibrutinib, currently offer therapeutic promise, accumulating
evidence actually supports a potential role for TLR agonists in the
treatment of some hematopoietic malignancies as well. Recent
work by Ignatz-Hoover and colleagues (87), for example, demonstrated that the TLR7/8 agonist R848 promotes in vitro terminal
differentiation and inhibits proliferation of AML cell lines and
primary patient samples in a TLR8–MyD88–p38-dependent
fashion. Furthermore, R848 significantly inhibited AML tumor
growth in an AML NSG mouse xenograft model. In human
myeloma cell lines, stimulation with polyinosinic–polycytidylic
acid (poly I:C), an agonist of TLR3, led to increased apoptosis and
induced activation of the NFκB pathway and type I IFN secretion,
thereby inhibiting cell growth. Poly I:C also led to TLR3 upregulation, type I IFN induction, and increased apoptosis in primary
AML cells (88, 89). Similarly, treatment of ALL cell lines and primarily ALL samples with the specific TLR2/1 ligand, PAM3CSK4,
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SUMMARY AND FUTURE DIRECTIONS
Toll-like receptors have a well-established role in innate immunity
and inflammation upon stimulation by foreign pathogens and
endogenous DAMPS. The type of ligand, in part, dictates both the
subcellular localization of the TLR and the unique downstream
signaling pathways that are activated, leading to numerous cellular effects, including cytokine secretion and regulation of gene
expression. While the role of TLR signaling in committed effector
immune cells has been extensively studied, recent evidence suggests these receptors can also influence earlier precursor HSC and
progenitor populations. The expression of multiple TLRs has been
described in normal HSCs as well as in stromal cells of the bone
marrow niche. Upon stimulation, TLRs either directly activate
HSCs or act indirectly on them through the production of proinflammatory cytokines by bone marrow niche cells or immune
effector cells (Figure 2). While some degree of TLR signaling may
be essential for the development of a normal immune response,
accumulating data show an association between enhanced TLR
expression and signaling and hematopoietic disorders and malignancies, such as MDS and lymphoid neoplasms (Table 1).
As discussed herein, numerous studies have linked altered
TLR signaling to hematopoietic dysfunction and malignancy,
supporting a role for this signaling in the pathogenesis of these
diseases. However, in many cases, questions remain regarding the
etiology of the increased TLR expression and signaling and the
precise contribution of this signaling to the initiation and/or progression of disease. Inflammatory signals themselves, including
cytokines such as IFN-gamma and G-CSF and TLR ligands such
as LPS, have been shown to upregulate TLR expression on various
bone marrow cell types (42, 105–108). Thus, a proinflammatory
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FIGURE 2 | TLR signaling influences both normal and premalignant HSCs. TLR agonists may both directly (solid lines) and indirectly (dashed lines) influence
HSCs. In normal HSCs, TLR signals promote myeloid differentiation and mobilization, and sustained exposure to TLR agonists can result in reduced HSC function.
In MDS and other hematopoietic malignancies, enhanced TLR signaling (via increased expression or, in the case of MDS, acquisition of the activating TLR2-F217S
variant or increased TRAF6 activity in 5q- cases) may contribute to ineffective hematopoiesis and leukemogenesis.

tumor microenvironment could contribute to the increased
TLR expression seen in multiple hematopoietic malignancies.
Furthermore, for some TLRs, including TLR2, 4, and 5, membrane receptor expression shifts to cytoplasmic during dysplastic
transformation in solid tumors (109). In addition, endogenous
ligands, including HMGB1, are capable of translocating to the
cytoplasm upon malignant transformation (109, 110), suggesting
the possibility that alterations in the subcellular locations of TLRs
and their ligands could contribute to enhanced TLR signaling in
hematopoietic malignancies. Further studies will be needed to
investigate these ideas and determine the factors that influence
TLR expression and signaling in premalignant and malignant
hematopoietic cells.
In addition to questions regarding the stimulus for enhanced
TLR expression and signaling in hematopoietic neoplasms, in
many cases, the significance of this signaling to the pathogenesis of
disease is not well understood, and additional studies are needed
to determine the effects of augmenting or inhibiting TLR signaling on disease outcomes (i.e., severity of cytopenias, and initiation
and/or progression of leukemia). Furthermore, while multiple
different TLRs have been shown to have elevated expression in
various tumors, it is not clear to what extent these different receptors may confer unique signals leading to the promotion of tumor
development (In other words, does all TLR signaling generally
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have the same impact on premalignant and malignant cells, or do
different TLRs ultimately influence downstream mediators that are
unique to particular receptors?). Furthermore, the downstream
mediators of TLR signaling that regulate HSC cycling, differentiation, and function, and that ultimately therefore may promote
leukemogenesis, are not well known. And finally, the contribution
of cell-autonomous versus cell non-autonomous TLR signaling
to hematopoietic malignancies is not well understood. Although
the expression and signaling of TLRs is known to be increased
on the CD34+ cells of MDS patients, for example, as well as the
leukemia cells in various myeloid and lymphoid cancers, it is not
known whether other cell types within the bone marrow microenvironment (hematopoietic and stromal) also display aberrant
TLR signaling, and what role this non-autonomous signaling may
play in the pathogenesis of the disease.
In line with the lack of detailed understanding of the role
of TLR signaling in many hematopoietic malignancies, several
questions remain regarding the utility of targeting these receptors
therapeutically. As discussed above, TLR expression and signaling
is generally enhanced in hematopoietic neoplasms, and therefore
inhibition of TLR signaling is a logical therapeutic strategy. While
TLR antagonists are under investigation currently in select cases
(OPN-305 in MDS and Ibrutinib in WM, for example), there
are multiple studies conversely showing an antitumor effect of
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TLR stimulation, with TLR agonists either directly affecting cell
growth and chemosensitivity or indirectly supporting tumor
cell death via promotion of an antitumor immune response. A
more defined understanding of the mechanism through which
TLRs influence hematopoietic neoplasms is therefore necessary
to better delineate the utility of TLR agonists versus antagonists
as novel therapeutic options and balance the potential benefits
of reducing hyperactivated TLR signaling on hematopoiesis with
the risks of suppressing the immune response against the tumor
cells as well as infections (111).
Based on the studies discussed within, it has become increasingly apparent that the effects of TLR signaling on tumor growth
and progression requires careful consideration of numerous

factors, including the TLR in question, unique downstream
effectors, the influence of the tumor microenvironment, and the
tumor type. Future studies aimed at gaining a comprehensive
mechanistic understanding of the role of TLR signaling in
lymphoproliferative disorders, MDS, and other hematopoietic
neoplasms are required to more fully appreciate the influence
of this signaling on disease pathogenesis and determine the
appropriate utility of TLR agonists and antagonists as therapeutic agents.
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